Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference (Businesswire) - May 1, 2024 - "Endeavor BioMedicines...announced that data from a completed Phase 2a clinical trial evaluating the company's lead investigational candidate ENV-101 in patients with idiopathic pulmonary fibrosis (IPF) will be presented for the first time in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference. ATS 2024 will take place May 17-22, 2024, in San Diego. The Phase 2a, randomized, double-blind, placebo-controlled clinical trial (NCT04968574) evaluated the safety and efficacy of ENV-101 vs. placebo in 41 patients with confirmed IPF who were treated for 12 weeks....Based on results from the Phase 2a trial of ENV-101, Endeavor BioMedicines intends to initiate a Phase 2 trial in patients with IPF and in a parallel cohort, patients with progressive pulmonary fibrosis (PPF), in 2024."
New P2 trial • P2a data • Idiopathic Pulmonary Fibrosis • Immunology
|